secwatch.observer — SEC 8-K summary
======================================

Issuer:     TG THERAPEUTICS, INC. (TGTX)
CIK:        0001001316
Form:       8-K
Filed at:   2024-01-10T23:59:59+00:00
Accession:  0001437749-24-001061
Event type: other_material
Sentiment:  positive
Materiality: 0.80
Item codes: 1.01, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

TG Therapeutics licenses azer-cel, reports preliminary Q4 BRIUMVI revenue $40M, FY2024 guidance $220-260M
--------------------------------------------------------------------------------

- Upfront payment to Precision: $7.5M ($5.25M cash + $2.25M equity); deferred $2.5M equity; up to $288M milestone payments plus high-single-digit to low-double-digit royalties.
- Preliminary Q4 2023 BRIUMVI U.S. net product revenue ~$40M, full year ~$89M; year-end cash ~$215M.
- 2024 guidance: BRIUMVI U.S. net product revenue target $220-260M, Q1 target $41-46M; operating expense ~$250M.
- 2024 pipeline milestones: start trials for subcutaneous BRIUMVI, BRIUMVI in other autoimmune diseases, and azer-cel in autoimmune disease.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1001316/000143774924001061/0001437749-24-001061-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1001316/000143774924001061/tgtx20240109_8k.htm
  HTML page:      https://secwatch.observer/filing/0001437749-24-001061

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer